Replagal Enzyme Replacement Therapy for Children With Fabry Disease
NCT00084084
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Fabry Disease
Interventions
DRUG:
Agalsidase alfa
Sponsor
Shire